CME/CE podcast

1
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

for 15 weeks siden

Spill senere

Lister

Lik

Likt

—

Host: Jorge E. Cortes, MD Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require further treatment with second- and third-line therapy. The development of newer drugs with unique mechanisms that can overcome these resistance phenotypes offers new treatment strategies that can maintain response rates. This activity reviews the current treatment options for newly diagnosed disease and the importance of integrating patient preference when planning therapeutic regimens.…

1
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

for 19 weeks siden

—

Host: Mark Socinski, MD This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.…

1
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

for 30 weeks siden

—

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025: On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting. On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.…

1
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

for 33 weeks siden

—

Host: Helena Yu, MD The treatment of EGFR- mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR- mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.…

1
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

for 40 weeks siden

—

Host: Matthew S. Davids, MD, MMSc Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL. In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can ……

1
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

for 41 weeks siden

—

Host: Joshua E. Reuss, MD Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC. In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are ……

1
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting

for 48 weeks siden

—

Host: Matthew Lunning, DO, FACP In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management. In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease. This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate ……

$25 PlayStation Store Gift Card [Digital Code]

Amazon Basics Dog and Puppy Pee Pads with Leak-Proof Quick-Dry Design for Potty Training, Standard Absorbency, Regular Size, 22 x 22 Inches, Pack of 100, Blue & White

Apple AirPods Pro 2 Wireless Earbuds, Active Noise Cancellation, Hearing Aid Feature, Bluetooth Headphones, Transparency, Personalized Spatial Audio, High-Fidelity Sound, H2 Chip, USB-C Charging

Amazon Fire TV Stick HD (newest model), free and live TV, Alexa Voice Remote, smart home controls, HD streaming

Amazon Basics Multipurpose Copy Printer Paper, 8.5" x 11", 20 lb, 8 Reams, 4000 Sheets, 92 Bright, White

Mini Mic Pro Wireless Microphone for iPhone, iPad, Android, Lavalier Microphone for Video Recording - 2 Pack iPhone Mic Crystal Clear Recording with USB-C for Podcast, ASMR

Bounty Quick Size Paper Towels, White, 8 Family Rolls = 20 Regular Rolls (Packaging May Vary)

everydrop by Whirlpool Ice and Water Refrigerator Filter 1, EDR1RXD1, Single-Pack , Purple

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Podcaster verdt å lytte til

1
Mind The Business: Small Business Success Stories

CME/CE

CME/CE

Podcaster verdt å lytte til

Alle episoder

1
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

1
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

1
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

1
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

1
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

1
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

1
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting

Velkommen til Player FM!

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

TERRO Ant Killer Bait Stations T300B - Liquid Bait to Eliminate Ants - 12 Count Stations for Effective Indoor Ant Control

Ailun 3 Pack Screen Protector for iPhone 16 Pro Max [6.9 inch] + 3 Pack Camera Lens Protector with Installation Frame,Sensor Protection,Dynamic Island Compatible,Case Friendly Tempered Glass Film

Mighty Patch™ Original patch from Hero Cosmetics - Hydrocolloid Acne Pimple Patch for Covering Zits and Blemishes in Face and Skin, Vegan-friendly and Not Tested on Animals (36 Count)

Bounty Paper Towels Quick Size, White, 16 Family Rolls = 40 Regular Rolls (Packaging May Vary)

Peacock TV

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Minecraft

Amazon Basics Multipurpose Copy Printer Paper, 8.5 x 11 inches, 20 lb, 1 Ream, 500 Sheets, 92 Bright, White

TurboTax Deluxe 2024 Tax Software, Federal & State Tax Return [PC/MAC Download]

2025 Topps Series 1 Baseball - Factory Sealed - Value Box

2025 - American Silver Eagle .999 Fine Silver with our Smyrnacoin Certificate of Authenticity Dollar Uncirculated US Mint

Amazon eGift Card - Amazon Logo (Animated)

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

$25 PlayStation Store Gift Card [Digital Code]

Amazon Basics Dog and Puppy Pee Pads with Leak-Proof Quick-Dry Design for Potty Training, Standard Absorbency, Regular Size, 22 x 22 Inches, Pack of 100, Blue & White

Apple AirPods Pro 2 Wireless Earbuds, Active Noise Cancellation, Hearing Aid Feature, Bluetooth Headphones, Transparency, Personalized Spatial Audio, High-Fidelity Sound, H2 Chip, USB-C Charging

Podcaster verdt å lytte til

CME/CE

CME/CE

Podcaster verdt å lytte til

Velkommen til Player FM!

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Minecraft

Amazon Basics Multipurpose Copy Printer Paper, 8.5 x 11 inches, 20 lb, 1 Ream, 500 Sheets, 92 Bright, White

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Hurtigreferanseguide